Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.

about

Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.

Item

http://www.wikidata.org/entity/Q51307105

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Sestrin-3 modulation is essent ...... itacin B in lung cancer cells.

@en

Sestrin-3 modulation is essent ...... itacin B in lung cancer cells.

@nl

type

Item

label

Sestrin-3 modulation is essent ...... itacin B in lung cancer cells.

@en

Sestrin-3 modulation is essent ...... itacin B in lung cancer cells.

@nl

prefLabel

Sestrin-3 modulation is essent ...... itacin B in lung cancer cells.

@en

Sestrin-3 modulation is essent ...... itacin B in lung cancer cells.

@nl

P1476

Sestrin-3 modulation is essent ...... itacin B in lung cancer cells.

@en

P2093

Eiman Mukhtar

http://www.w3.org/2001/XMLSchema#string

Farah Jajeh

http://www.w3.org/2001/XMLSchema#string

Hasan Mukhtar

http://www.w3.org/2001/XMLSchema#string

Mohammad Imran Khan

http://www.w3.org/2001/XMLSchema#string

Naghma Khan

http://www.w3.org/2001/XMLSchema#string

Sameh M Shabana

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

AMPK phosphorylation of raptor mediates a metabolic checkpoint

FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Signal transduction by receptors with tyrosine kinase activity

TOR, a central controller of cell growth.

P304

184-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CARCIN/BGW124

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27881463

http://www.w3.org/2001/XMLSchema#string

P932

6075515

http://www.w3.org/2001/XMLSchema#string